Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis.
Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. Fournier CN, et al. Among authors: salameh js. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):242-249. doi: 10.1080/21678421.2017.1421666. Epub 2018 Jan 8. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29308669
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.
Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, Cudkowicz ME, Atassi N. Babu S, et al. Among authors: salameh js. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):15-23. doi: 10.1080/21678421.2019.1672750. Epub 2019 Oct 14. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31608711 Clinical Trial.
Amyotrophic Lateral Sclerosis: Review.
Salameh JS, Brown RH Jr, Berry JD. Salameh JS, et al. Semin Neurol. 2015 Aug;35(4):469-76. doi: 10.1055/s-0035-1558984. Epub 2015 Oct 6. Semin Neurol. 2015. PMID: 26502769 Review.
Characteristics of amyotrophic lateral sclerosis in Lebanon-a chart review.
Malek E, Ismail H, Doumiati H, Salameh J. Malek E, et al. Among authors: salameh j. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(7-8):614-619. doi: 10.1080/21678421.2020.1788095. Epub 2020 Jul 7. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 32633637
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group. Weiss MD, et al. Among authors: salameh js. Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24. Neurology. 2016. PMID: 26911633 Free PMC article. Clinical Trial.
Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis.
Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, Tan W, Salameh J, McKenna-Yasek DM, Smith T, Peng L, Moore MJ, Brown RH Jr, Cai H, Xu Z. Yang C, et al. Among authors: salameh j. Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):E1121-9. doi: 10.1073/pnas.1322641111. Epub 2014 Mar 10. Proc Natl Acad Sci U S A. 2014. PMID: 24616503 Free PMC article.
158 results